Progression is independent of relapse activity in early multiple sclerosis: a real-life cohort studyEmilio Portaccio, Maria Pia Amato, Angelo Bellinvia et al.|Brain|2022Cited by 158
Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International CohortsSifat Sharmin, Éric Berger, Dana Horáková et al.|CNS Drugs|2021Cited by 12